Cannabis Europa London, 2026: First Major Gathering After Rescheduling Has Changed The Game

Last week’s announcement of rescheduling threw many operators into a bind. For now, the US medical cannabis industry is much smaller than other markets and as a result, it’s not viewed by many operators as a high priority. 

Todd Blanche has made an announcement that was more important than just adjusting a tax situation or relaxing a research bar. Cannabis is now officially recognized as having medicinal benefits by moving it from Schedule III. 

The US Federal policy is now closer to European standards. This is because the legal framework underpinning the US rescheduling, which was based on a section of the Controlled Substances Act that was designed to align US drug laws with the 1961 UN Single Convention on Narcotic Drugs. It’s the same international regulatory framework used in Europe for medical cannabis. 

Next month, the cannabis industry will be focusing on the convergence of operators, investors and regulators, as well as patients, from both sides. Cannabis Europa London 2026. 

Prohibition Partners’ flagship event this year will provide the first chance for those industry players at the center of convergence to explore the next stage of the cannabis industry now that the largest regulatory change for cannabis policies in over half a decade has been implemented. 

Cannabis Europs will return to The Barbican, London between May 26-27. More than 700 speakers and more than 1,000 delegates are expected to attend to discuss the new dynamics of this transatlantic relationship. 

It will take place on a shared stage between the senior management teams of North America’s largest medical marijuana operators and European counterparts. Policy makers, investors and policy makers are invited to examine what an ideal world would be like where Europe and America share one medical cannabis framework.

In addition to the many sessions that will address these topics and their implications on a global scale, one session dedicated to UN drug policy, international law, and patient access, examines whether or not the incremental improvements of the past few years are sufficient. Or, whether a more comprehensive rethinking about cannabis and its place in international law, is necessary for meaningful, worldwide patient accessibility. 

An intimate discussion with Saphira Golob, from the US Cannabis Roundtable, and Bryan Lanza, who was a member of Trump’s Transition Team, will put the US in the spotlight and explore what the actual rescheduling of events would look like.

Cannabis Europa will be the place where the leaders of both the Atlantic and the Canadian cannabis industries come together next month. This is a momentous occasion in the history the cannabis sector. The conversations that take place this year at the Cannabis Europa event, are going to help define the future of this industry.

The rescheduling announced last week threw many operators into a bind. For now, the US medical cannabis industry is much smaller than other markets and as a result, it’s not viewed by many operators as a high priority. 

Todd Blanche has made an announcement that was more important than just adjusting a tax situation or relaxing a research bar. The first official recognition of cannabis’ medical value is made by shifting it to Schedule III. 

The US Federal policy is now closer to European standards. This is because the legal framework underpinning rescheduling, which is a section of the Controlled Substances Act that was designed to align US drug laws with the 1961 UN Single Convention on Narcotic Drugs (UN SCD), has the same international structure as the medical cannabis regulations in Europe. 

Next month, the cannabis industry will be focusing on the convergence of operators, investors and regulators, as well as patients, from both sides. Cannabis Europa London 2026. 

Prohibition Partners’ flagship event this year will provide the first chance for those industry players at the center of convergence to explore the next stage of the cannabis industry now that the largest regulatory shift for the cannabis industry in over 50 years has been implemented. 

Cannabis Europs will return to The Barbican, London between May 26-27. More than 700 speakers and more than 1,000 delegates are expected to attend to discuss the new dynamics of this transatlantic relationship. 

It will take place on a shared stage between the senior management teams of North America’s largest medical marijuana operators and European counterparts. Policy makers, investors and policy makers are invited to examine what an ideal world would be like where Europe and America share one medical cannabis framework.

A dedicated session will be held on UN Drug Policy and International Law to examine if the progress made in recent years has been sufficient or if a more radical rethinking of cannabis is needed for global access. 

An intimate discussion with Saphira Goloob, from the US Cannabis Roundtable, and Bryan Lanza, who was a member of Trump’s Transition Team, will put the US in the spotlight and explore what the actual rescheduling of events would look like.

Cannabis Europa will bring together the top voices in cannabis from across the Atlantic next month, at an important moment for the history of this industry. The conversations that take place this year at this event are going to help shape this sector over the coming decade.

Cannabis Law Resources for Poland

Browse essential legal pages on cannabis sales and cultivation in Poland. You can use these resources to learn about the requirements for certification, permissions and compliance.

• 
  Polish News Registration and Interests of Cannabis Businesses
  
• 
  Permissions for Cannabis Sales in Poland
  
• 
  Authorization for Importing or Manufacturing Medical Products
  
• 
  Permission for Manufacturing or Importing Medical Products
  
• 
  Certificate of Good Manufacturing Practices (GMP)
  
• 
  Registration of Medical Products in Poland